Ustekinumab-aekn — Point32Health
Psoriatic Arthritis
Preferred products
- Yesintek
Initial criteria
- Documented diagnosis of psoriatic arthritis
- Patient age ≥ 6 years
- Prescribed by or consultation with a rheumatologist or dermatologist
- Trial and failure of at least two of the listed medications from each of the following therapeutic categories (only one medication is required if only one is available): Interleukin Antagonists: Bimzelx, Skyrizi, Taltz, Tremfya; Janus Kinase Inhibitors: Rinvoq, Xeljanz; Phosphodiesterase 4 inhibitors: Otezla; Selective T Cell Stimulators: Orencia; Tumor Necrosis Factors: Cimzia, Enbrel, Humira, Simponi OR Contraindication to all the following medications: Bimzelx, Skyrizi, Taltz, Tremfya, Rinvoq, Xeljanz, Otezla, Orencia, Cimzia, Enbrel, Humira, and Simponi
- Documented previous failure of or clinical inappropriateness of treatment with Yesintek